Figure 2.
Figure 2. Transcriptional signatures of PBMCs in patients with AML exhibiting robust vs weak CRT exposure on blasts. (A-B) Expression levels of genes from the Human Immune Panel TaqMan low-density array in PBMCs from 13 CRTHi vs 13 CRTLo patients with AML prior to the initiation of induction chemotherapy (A), or at recovery of normal hematopoiesis (B). The Mann-Whitney test was employed to assess intergroup variations. (C) qRT-PCR–assisted quantification of CD8A, CD28, CXCR3, IFNG, IL2, IL2RA, TBX21, FASLG, GNLY, GZMB, PRF1, CCL5, CCR4, CCR4, CCR5, CD40LG expression levels in PBMCs from 13 CRTHi vs 13 CRTLo patients with AML prior to the initiation of induction chemotherapy, or at recovery of normal hematopoiesis. Box plots: lower quartile, median, upper quartile; whiskers, minimum value, maximum value.

Transcriptional signatures of PBMCs in patients with AML exhibiting robust vs weak CRT exposure on blasts. (A-B) Expression levels of genes from the Human Immune Panel TaqMan low-density array in PBMCs from 13 CRTHi vs 13 CRTLo patients with AML prior to the initiation of induction chemotherapy (A), or at recovery of normal hematopoiesis (B). The Mann-Whitney test was employed to assess intergroup variations. (C) qRT-PCR–assisted quantification of CD8A, CD28, CXCR3, IFNG, IL2, IL2RA, TBX21, FASLG, GNLY, GZMB, PRF1, CCL5, CCR4, CCR4, CCR5, CD40LG expression levels in PBMCs from 13 CRTHi vs 13 CRTLo patients with AML prior to the initiation of induction chemotherapy, or at recovery of normal hematopoiesis. Box plots: lower quartile, median, upper quartile; whiskers, minimum value, maximum value.

Close Modal

or Create an Account

Close Modal
Close Modal